Flavonoids from Radix Tetrastigae improve LPS-induced acute lung injury via the TLR4/MD-2-mediated pathway

DAN-DAN LIU¹ ², GANG CAO¹, LI-KAI HAN³, YI-LU YE², QI ZHANG², YU-HAN SIMA⁴ and WEI-HONG GE¹

¹Department of Pharmacy, Zhejiang Chinese Medical University; ²Department of Basic Medicine, Zhejiang Medical College, Hangzhou, Zhejiang 310053; ³Pathological Department, People’s Hospital of Zhejiang, Hangzhou, Zhejiang 310046; ⁴Hangzhou Xuejun High School, Hangzhou, Zhejiang 310012, P.R. China

Received July 21, 2015; Accepted May 27, 2016

DOI: 10.3892/mmr.2016.5412

Abstract. Total flavonoids isolated from Radix Tetrastigae (RTFs) possess immunomodulatory activity, particularly on inflammation. In mice with lipopolysaccharide (LPS)-induced acute lung injury (ALI), treatment with RTFs at 40, 80 and 160mg/kg significantly reduced leukocyte infiltration, improved histopathological changes in lung tissues and decreased the LPS-induced production of several inflammatory mediators in the bronchoalveolar lavage fluid (BALF), which included the chemotactic factors, granulocyte colony-stimulating factor, monocyte inflammatory protein-1α and B-lymphocyte colony inflammatory cytokines, including interleukin (IL)-1β, IL-6, IL-12p40 and tumor necrosis factor-α, in a dose-dependent manner. In addition, the expression of the Toll-like receptor 4 (TLR4)/myeloid differentiation factor-2 (MD-2) compound, the phosphorylation of p38 mitogen-activated protein kinase (p38MAPK), c-Jun N-terminal kinase (JNK) and nuclear transcription factor-κB (NF-κB), in addition to the DNA binding activity of NF-κB p65 in lung tissues, were all attenuated following RTF treatment. However, RTF treatment had no effect on extracellular signal-regulated kinase (ERK). In conclusion, RTFs contributed to the regulation of LPS-induced ALI through the TLR4/MD-2-mediated NF-κB, JNK and p38MAPK pathways. This may be a potential therapeutic option for the treatment of inflammatory diseases.

Introduction

Acute lung injury (ALI) and its severe manifestation, acute respiratory distress syndrome (ARDS), are well-known life-threatening diseases with high morbidity rates (35-50%) in critically ill patients (1). The multiple etiologies, including severe sepsis, pneumonia, lung abscess and severe burns, cause uncontrolled and self-amplified pulmonary inflammation, which are at the center of the pathology of ALI/ARDS (2-5). Studies have been confirmed that the alveolar epithelium and pulmonary endothelium are the primary injury targets of this disease (3-6). Although substantial progress has been made in understanding the pathogenesis and pathophysiology of ALI/ARDS, the treatment remains limited.

It has been confirmed that intratracheal instillation of the endotoxin, lipopolysaccharide (LPS), can reproducibly induce ALI (7). LPS induces inflammatory cell infiltration into lung tissues, causing the release of proinflammatory cytokines, reactive oxygen species and chemotactic factors (8). These changes can cause lung edema, alveolar hemorrhage and substantial inflammation. In mammals, the Toll-like receptor 4 (TLR4)/myeloid differentiation factor-2 (MD-2) complex constitutes an essential component of the LPS receptor system (9). Common downstream signal transduction pathways of TLR4/MD-2, which have been shown to mediate inflammatory responses in lung injury, include nuclear factor-κB (NF-κB) and mitogen-activated protein kinases (MAPKs) (10). Major signaling pathways regulating cellular growth and the responses to cytokines and stress occur through the conserved MAPK family, which consists of p42/44 extracellular signal-regulated kinase (ERK), p38 MAPK and c-Jun N-terminal kinase (JNK) (11). NF-κB is a critical transcription factor required for maximal expression of several cytokines, and is involved in the pathogenesis of acute lung injury. Reports have demonstrated that the severity of inflammation in ALI/ARDS is markedly reduced by inhibition of the NF-κB signaling pathway (12-15). Therefore, drugs focusing on downregulating the TLR4/MD-2-mediated MAPK and NF-κB signaling pathways have a potent therapeutic effect for the treatment of ALI (16).

Radix Tetrastigae (RT) is a commonly used Chinese traditional medicine. The total flavonoid compounds isolated from RT (RTFs), the root of Tetrastigma hemsleyanum Diels
et Gilg), are the predominant active ingredients and have wide biological and pharmacological functions, including antitumor, liver-protecting, antiviral, anti-inflammatory, immunoregulatory effects and other pharmacological effects, with the exception that it is basically non-toxic (17-19). The present study investigated the effect of RTFs on mice with LPS-induced ALI for the first time, to the best of our knowledge. Elucidation of the mechanisms, TLR4/MD-2-mediated MAPK and NF-κB signaling pathways and associated downstream regulators were also investigated, with the aim of determining the therapeutic effects of RTFs on ALI.

Materials and methods

Flavonoid isolation. The total flavonoids were extracted from RT, according to the method previously reported (20) with mild revision. Briefly, decocation powder of RT from Guizhou (China) was extracted twice with 60% ethanol (v/w) in a boiling water bath for 90 min, followed by filtering and concentration using reduced pressure distillation. The crude extracts were dissolved in water and purified through resin HPD826. Total flavonoid extracts were obtained with further distillation under a vacuum with lyophilization of the eluant. The quality of the total flavonoid extract was determined using colorimetric HCl-Mg and aluminum chloride reactions, followed by high-performance liquid chromatography (20,21).

Animals. Male BALB/c mice (n=60) were purchased from SLRC Laboratory Animal, Ltd. (Shanghai, China). These mice used in the present study were ~10-week old mice (20-25 g), matched for age and weight. The animals were maintained in room with regulated temperature (22-24°C), humidity (55±5%) and light (12 h light-dark cycle), and with access to food and water ad libitum. All procedures were performed in accordance with the Guidelines for Animal Experimentation of Zhejiang University (Zhejiang, China).

Mouse model of ALI. The mice were randomly divided into five groups (n=12/group): Control [phosphate-buffered saline (PBS)]; model (2.5 mg/kg LPS) and TRF (40, 80 or 160 mg/kg+2.5 mg/kg LPS). All mice were challenged intratracheally with either 25 µl PBS alone or 25 µl PBS containing 25 µg LPS (per 10 g body weight) under anesthesia with intraperitoneal injection of chloral hydrate (400 mg/kg). The mice were intragastrically administered with 100 µl PBS or RTF 30 min prior to LPS challenge and for 2 days after LPS challenge. On the 4th day, mice were anesthetized with chloral hydrate (0.4 g/kg; Sigma-Aldrich; St. Louis, MO, USA) to collect the bronchoalveolar lavage fluid (BALF) and lung tissues and then sacrificed by overdose of chloral hydrate. The severity of lung injury was assessed by pathological changes in the lung tissues and cellular profiles in the BALF.

Collection of BALF and leukocyte counting. The BALF was collected, as previously described (22). Briefly, under anesthesia, the trachea was cannulated and the lungs were lavaged three times with PBS (0.5 ml each time). The collected BALF was centrifuged at 200 x g for 5 min at 4°C, and the supernatant was frozen at -80°C for subsequent biochemical analysis. The pelleted cells were then re-suspended in PBS for cell counting. The numbers of leukocytes were enumerated using a hemocytometer. For differential counts, smears of the BALF cells (~10³ cells/ml) from each mouse were prepared by centrifugation (4°C at 200 x g for 5 min) and then stained with Wright-Giemsa solution.

Inflammatory cytokine antibody array and ELISA. The secretion of different cytokines from the BALF was measured using a semi-quantitative mouse inflammation antibody array from RayBiotech (Guangzhou, China). In brief, antibodies against 40 different inflammatory cytokines were spotted onto the cytokine array by the manufacturer. Initially, 100 µl blocking buffer was added each well and incubated at room temperature for 30 min to block the slides. Subsequently, 100 µl sample was added to each sub-array at room temperature overnight, prior to incubation with biotin-conjugated primary antibodies. Following washing, Cy3-conjugated streptavidin was added for 2 h. Finally the chip was scanned using a GenePix 4000B microarray scanner (Molecular Devices, Sunnyvale, CA, USA). The images were analyzed using the GenePix Pro 5.0 software program (Molecular Devices), and the levels of cytokines were quantified according to the standard curve calibrated from the same array.

The secretion of interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-6 and IL-12p40 in the BALF were further measured using an eBioscience ELISA kit (eBioscience, San Diego, CA, USA), according to the manufacturer’s protocol. In addition, activation of the MAPK pathway in the lung tissues was also detected using ELISA kits (Elisa Biotech, Shanghai, China), including p38, phosphorylated (p)-p38, ERK, p-ERK, JNK and p-JNK.

Histopathologic examination of lung tissues. To characterize the histological alterations in the lung tissues, the lungs were excised and fixed in 10% buffered formalin. After dehydration with graded alcohol and embedding in paraffin, the lung tissues were cut into 4 µm sections, and subsequently stained with hematoxylin and eosin. The lung injury was scored by an observer in a blinded-manner under a light microscope, according to pathological changes, including cell infiltration and accumulation, pulmonary edema, hemorrhage and the thickness of the alveolar wall. Each indicator was graded according to a five-point scale: 0=minimal damage, 1=mild damage, 2=moderate damage, 3=severe damage and 4=maximal damage. Therefore, the severity of lung injury was assessed according to the sum of the individual indicator scores (23).

Western blot analysis of lung tissues. The lung tissues were homogenized and quantified using a BCA protein assay kit (Pierce Biotechnology, USA). Each protein sample (20 µg) was mixed with the sample buffer to a final concentration of 0.06 M Tris-HCl, pH 6.8, 2% SDS, 5% β-mercaptoethanol, 10% glycerol and 0.025% bromophenol blue. Equal quantities of protein were loaded per well, separated by SDS-PAGE and transferred onto PVDF membranes (EMD Millipore, Billerica, CA, USA). Subsequent to blocking with 5% nonfat milk for 1 h, the membranes were probed with monoclonal antibodies rabbit anti-mouse monoclonal antibodies against MD-2 (cat. no. sc-20668; Santa Cruz Biotechnology, Inc., Danvers, MA, USA), TLR4 (cat. no. DR4841 UcallM Biotechnology...
Co., Ltd., Beijing, China), NF-κB p65 (cat. no. 4764S) and p-NF-κB p65 (cat. no. 3033S) (Cell Signaling Technology, Beverly, MA, USA) overnight at 4°C. Membranes were then incubated with GAPDH-HRP mAb (LK9002T) and goat anti-rabbit secondary antibody (LK2001) (Sungene Biotech, Co., Ltd., Tianjing, China). The blots were normalized to GAPDH to correct for differences in loading of the proteins. Densitometric values of the immunoblot signals were obtained from three separate experiments using Pro 3DS 6.0 image software (National Institutes of Health, Bethesda, MA, USA).

NF-κB p65 activity assay. NF-κB activity was measured using an ELISA-based TransAM NF-κB kit (Active Motif, Carlsbad, CA, USA) on the nuclear protein extracts. The Nuclear Extract kit was obtained from Active Motif for the preparation of nuclear extracts from the lung tissues. The TransAM assay for NF-κB p65 activity was performed, according to the manufacturer's protocol (13,14). Briefly, oligonucleotides containing the NF-κB consensus binding site (5'-GGG ACT TCC-3') were immobilized on a 96-well plate. The active forms of NF-κB in the nuclear extracts were bound to the oligonucleotides on the plate and detected colorimetrically. The samples were measured at an absorbance of 450 nm on a spectrophotometer, with a reference wavelength of 650 nm.

Statistical analysis. All values are expressed as the mean ± standard deviation. Differences between the mean values of normally distributed data were assessed using one-way analysis of variance (Dunnett's t-test) and two-tailed Student's t-test using SPSS software v.19 (IBM, Armonk, NY, USA). P≤0.05 was considered to indicate a statistically significant difference.

Results

RTFs decreases LPS-induced leukocyte infiltration in the BALF. The recruitment of inflammatory cells into pulmonary alveoli is important in ALI. Following 3 days of LPS instillation, the levels of total leukocytes, neutrophils and macrophages in the BALF were significantly increased in all groups exposed to LPS, compared with those of the control group. RTF treatment (40, 80 and 160 mg/kg) significantly reduced LPS-induced leukocyte exudation (Fig. 1; P<0.05), particularly the numbers of neutrophils and macrophages (P<0.01).

RTFs attenuate the secretion of inflammatory factors in BALF. Elevation in the levels of proinflammatory cytokines is a typical response to LPS challenge. In the present study, the release of 40 inflammatory cytokines from the BALF of RTF-treated mice was determined using a mouse cytokine antibody array. In the microarray, any ≥1.5-fold increase or ≤0.65-fold decrease in signal intensity for a single analyte between samples or groups was considered a measurable and significant difference in expression, provided that the sets of signals were well above background (mean background ± two standard deviations; accuracy ~95%). Compared with the model, the release of B lymphocyte chemotactant (BLC), granulocyte colony stimulating factor (GCSF), IL-1β, IL-6, IL-12p40/p70, macrophage inflammatory protein-1α (MIP-1α), tissue inhibitor of metalloproteinase-1 (TIMP-1) and TNF-α induced by LPS were markedly reduced by RTF treatment (Fig. 2A). Among the eight factors, BLC, GCSF and MIP-1α belong to the family of chemotactic factors, which are predominantly involved in the infiltration of leukocytes. The downregulated expression levels of these factors were consistent with the numbers of leukocytes present in the BALF. These IL-1β, IL-6, IL-12p40 and TNF-α proinflammatory factors may be the functional cytokines in LPS-induced ALI.

The release of IL-1β, IL-6, IL-12p40 and TNF-α was also quantified using an ELISA assay. LPS treatment induced the release of cytokines to a maximum. The maximal induction for IL-6 was 220±11 pg/ml, which was ~5-fold of that in the control. Compared with the model, the production of cytokines in the RTF-treated groups were significantly reduced in a dose-dependent manner (Fig. 2B). By comparing the results from the cytokine array analysis, the results from the ELISA assay revealed a more marginal change between groups, which may be accounted for by the sensitivity of the two different assay systems.

RTFs ameliorate histopathologic changes in the lung tissues of ALI. The severity of LPS-induced ALI was further evaluated. As shown in Fig. 3, the control group showed normal structures, and no histopathological changes were observed in the lung tissues. However, following challenge with LPS, the pulmonary function of the LPS group was markedly impaired, with various changes, including capillary congestion, hemorrhage, the infiltration or aggregation of neutrophils in airspace or vessel wall and thickening of the alveolar wall. In the experimental groups, the histopathological changes were abated by RTF treatment. In addition, similar inhibitory effects were exhibited in the semi-quantitative assay, in which histological changes were scored. The lung injury scores increased in the LPS-treated groups, however, the increase was significantly reduced by RTF treatment (Fig. 3; P<0.01). These results demonstrated that RTF treatment attenuated the severity of lung injury in the ALI mice induced by LPS, and improved the condition of the lung tissues.
RTFs inhibit the expression levels of TLR4 and MD-2 in lung tissues of ALI. To examine the mechanism underlying the anti-inflammatory effect of RTFs, the expression levels of TLR4 and MD-2 in the lung tissues were analyzed. LPS instillation markedly increased the protein levels of TLR4 and MD-2 in the mouse lungs (Fig. 4A), compared with the control. However, RTF treatment significantly inhibited the expression levels of TLR4 and MD-2 induced by LPS. As shown in Fig. 4B, the inhibitory effect was more marked on MD-2, compared with TLR4.

RTFs reduce NF-κB phosphorylation and DNA binding activity in lung tissues of ALI. NF-κB is an important upstream transcription factor, which induces the mRNA expression of various proinflammatory cytokines following stimulation with LPS. Western blot analysis (Fig. 4A and B) of the total protein extracts from the lung tissues showed that LPS treatment stimulated the expression and phosphorylation of NF-κB p65 (Fig. 4C and D), which was also significantly downregulated by RTFs (P<0.05). Furthermore, the effect of RTF on the transactivation of NF-κB was also detected. As shown in Fig. 4E, RTFs significantly reduced the DNA binding activity of NF-κB in the nuclear extracts from lung tissues of the LPS-induced ALI mice, which occurred in a dose-dependent manner, as determined using the TransAM NF-κB kit (P<0.05).

RTFs alleviate MAPK activation in the lung tissues of ALI. The MAPK signaling pathway is another important pathway involved in inflammatory responses. Following 3 days of
LPS instillation, the MAPKs in the model group, including p38, JNK and ERK, showed markedly upregulated levels of expression and phosphorylation in the lungs, compared with the control group (P<0.01). When the LPS‑induced ALI mice were treated with RTFs, the expression and phosphorylation levels of p38 and JNK were significantly reduced. ERK and p‑ERK exhibited marginal differences between the groups, however, these differences were not statistically significant (Fig. 5).

Discussion

According to the theory of traditional Chinese medicine, RT tuberous roots can promote the production of body fluid and blood circulation, which results in improved lung ventilation. RT roots have anti-inflammatory and immunomodulatory activities, which can be used to treat bronchitis, pneumonia, pharyngolaryngitis and viral meningitis. RT significantly inhibits HAc‑induced peritoneal capillary permeability, improves xylene-induced ear edema in mice and improves albumin-induced paw edema in rats (24). Feng et al (18) initially discussed the anti-inflammatory and antitoxic mechanisms from an immunological viewpoint; it was found that RT may be pivotal in the activation, proliferation and differentiation processes of T lymphocytes. Flavonoids are one of the predominant components in RT extract, therefore the present study aimed to elucidate the anti-inflammatory properties and mechanisms of RTF.

The recruitment of leukocytes is critical in the pathogenesis of ALI. It has been reported that neutrophil accumulation in the lung parenchyma is a histological hallmark of ALI (25). Leukocyte activation leads to the production of reactive oxygen species and granular enzymes, resulting in lung tissue injury by evoking an inflammatory cascade. In the present study, it was found that RTF significantly reduced the number of leukocytes in the BALF, including neutrophils and macrophages.
following LPS challenge. In addition, RTFs significantly reduced macrophage infiltration in the BALF, which is consistent with the findings in our in vitro investigation, in which RTF treatment inhibited LPS-stimulated RAW264.7 monocyte activation (26). These results showed that RTFs effectively attenuated pulmonary inflammation in LPS-induced ALI.

It is widely accepted that inflammatory cytokines are crucial in the pathogenesis of LPS-induced ALI. Several cytokines, particularly IL-1β, TNF-α and IL-6, have been identified as key factors in leukocyte infiltration in the lung tissues of ALI (27). In the present study, an inflammation microarray was used, which detected marked increases in the levels of a series of inflammatory mediators in the lung tissues following LPS instillation, including the chemotactic factors, GCSF, MIP-1α and BLC, and inflammatory cytokines, IL-1β, TNF-α, IL-6 and IL-12p40. However, the secretion of these mediators was all significantly reduced with RTF treatment. The change in chemotactic factors is consistent with the leukocyte infiltration in the BALF of the ALI mice. The production of inflammatory cytokines was further confirmed using an ELISA assay. The findings confirmed that the protective effect of RTFs on LPS-induced ALI may be attributed to the inhibition of pulmonary inflammatory responses.

Previous studies have indicated that TLR4 is the major signaling receptor in LPS-induced inflammatory
responses (28) by regulating the activities of downstream mediators, including MAPKs and NF-κB (29,30). MD-2, which has been shown to be essential for the correct intracellular distribution of TLR4 and efficient LPS recognition, mediates LPS-induced responses in vitro and in vivo (31-33). Accumulating evidence has shown that MD-2 is the critical receptor protein for LPS and is necessary for the ligand-dependent dimerization of the TLR4/MD-2 complex (31-33). The binding of the TLR4/MD-2 complex receptor by microbial products triggers a downstream signaling cascade, culminating in the activation of NF-κB, and promoter recognition sites direct the production of a number of pro-inflammatory cytokines, including IL-1β, TNF-α and IL-6 (34). In the present study, RTFs inhibited the expression of MD-2 and TLR4. Although the effect was more marked on MD-2, compared with TLR4, they synergistically led to a reduction in TLR4/MD-2 complex formation. These data suggested that RTFs may attenuate the severity of LPS-induced local inflammation, activated through the TLR4/MD-2-mediated signaling pathway.

Activation of the TLR4/MD-2 pathway initiates a series of MAPK and NF-κB cascades, and results in the overproduction of cytokines, including TNF-α and IL-6 (35). NF-κB is an important transcription factor in the LPS-TLR4 signaling pathway, regulating immune and inflammatory processes (36,37). The activation of MAPKs is critical in mediating a broad array of cellular responses, including cell proliferation and differentiation, transcription factor activation, and cytokine gene expression and production (38-40). Thus, inhibitors of NF-κB and MAPKs have been used as therapeutic drugs in clinical applications for inflammation-associated human diseases (41,42). In the present study, it was shown that RTFs potently suppressed LPS-induced NF-κB p65 activation. In addition to decreases in the expression and phosphorylation of NF-κB p65 in the total protein extracted from lung tissues, a reduction in DNA binding activity of intranuclear NF-κB p65 was also observed following RTFs treatment, suggesting that RTFs inhibited the mobilization of p65 into the nucleus and attenuated NF-κB-mediated signaling transduction. In addition, RTFs inhibited LPS-induced JNK and p38MAPK phosphorylation. Inhibition of the activation of JNK, p38MAPK and NF-κB result in decreases in the expression levels of cytokines, including IL-1β, IL-6, TNF-α and IL-12 (43). Thus, the inhibitory property of RTFs on LPS-induced generation of proinflammatory cytokines may be associated with the attenuated activation of JNK, p38MAPK and NF-κB.

The present study was the first, to the best of our knowledge, to demonstrate that total flavonoids isolated from RT significantly decreased the production of proinflammatory factors in an LPS-induced ALI mouse model. It was found that RTFs may interact with the expression and formation of the
TLR4/MD-2 complex to inhibit the action of LPS. RTF treatment protected the lung tissues of the ALI mice from excessive phosphorylation of JNK, p38MAPK and NF-κB, and down-regulated the expression and DNA-binding activity of NF-κB through the TLR4/MD-2 pathway. Collectively, the results of the present study provide novel insights into the mechanisms of RTFs as anti-inflammatory agents for LPS-mediated infections, which may be a potential therapeutic agent for septic shock.

Acknowledgements

The authors would like to thank Dr Weihong Ge for their expert guidance and support, and would like to thank the members of the pharmacological team and research department of Zhejiang Medical College for their assistance. This study was supported by the grant of Zhejiang Modernization of Traditional Chinese Medicine (grant no. 2010330).

References